ArticleCureus2025
Breast Cancer Surgery at a Tertiary Center in Greece: Clinicopathological Associations and Patient Outcomes.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Breast-conserving surgery (BCS) and mastectomy are the cornerstone surgical options for invasive breast cancer, yet their comparative effectiveness in real-world practice, especially when stratified by molecular subtype, remains inadequately characterized. In light of this, we conducted a single-center retrospective cohort study to evaluate clinicopathological features, treatment patterns, and overall survival (OS) among patients undergoing lumpectomy versus mastectomy at a tertiary care center in Greece. Methods A total of 119 women treated between 2010 and 2020 were included: 79 (66.4%) underwent lumpectomy and 40 (33.6%) underwent mastectomy. Clinicopathological variables [tumor size, histologic grade, stage, lymphovascular invasion (LVSI), nodal status, molecular subtype] and adjuvant therapies [chemotherapy, radiotherapy, sentinel lymph node biopsy (SLNB), axillary lymphadenectomy] were compared between groups. Survival analyses were performed using Kaplan-Meier estimates with log-rank tests and a multivariable Cox proportional hazards regression. Results Compared with the lumpectomy group, patients selected for mastectomy more frequently presented with tumors >2 cm [29/40 (72.5%) vs. 21/79 (26.6%), p<0.001], grade 3 disease [10/40 (25.0%) vs. 21/79 (26.6%), p=0.006], stage ≥2 [31/40 (77.5%) vs. 19/79 (24.0%), p<0.001], LVSI [20/40 (50.0%) vs. 21/79 (26.6%), p=0.011], and nodal involvement [20/40 (50.0%) vs. 9/79 (11.4%), p<0.001]. The distribution of molecular subtypes differed between groups (p=0.037), with luminal B-HER2 being most common overall [46/119 (38.7%)]. Radiotherapy was administered to all lumpectomy patients [79/79 (100.0%)] versus 10/40 mastectomy patients (25.0%, p<0.001). Kaplan-Meier analysis showed superior OS in the lumpectomy cohort (log-rank p=0.001); however, multivariable adjustment identified only higher clinical stage as an independent predictor of mortality [hazard ratio (HR) per stage increment: 8.32; 95% confidence interval (CI): 2.28-30.38; p<0.01], whereas type of surgery did not remain significant. Conclusions In our cohort of 119 patients, BCS yielded excellent survival outcomes in early-stage, lower-risk tumors, whereas mastectomy was more often reserved for more advanced disease. Clinical stage at diagnosis, rather than surgical approach per se, emerged as the primary determinant of OS. Integration of molecular subtype into surgical decision-making may further refine personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.